US Stem Cell Inc (USRM)

[Archery Class]

Yup, but this isn’t a traditional buy the hype, sell the news since no one could have called great earnings.

It was more of a knockdown on positive future. It’s impressive how hard these MM’s will push just to get the price down a few fractions of a cent. It’s indicative of those wanting in cheaper to ride it on up. To those who aren’t adding anymore, it’s annoying. To those who want to scoop cheap shares, it’s a gift.

Tomas has done what he said he would, focus on business while they have RMAT aspirations on the back burner. This is eventually .08 to .10 without RMAT hype, and we’ve already seen it get near .20 when that gets going again. To sustain long term levels, the company needs to hinge on more than just RMAT as a catalyst. The market is still punishing this company for their failure to achieve on first attempt.